体检报告总有小箭头？医生提醒：管好“坏胆固醇”是头等大事！

审核专家：方红娟

中国医科大学航空总医院内分泌科主任医师

参考文献

1.中国血脂管理指南修订联合专家委员会.中国血脂管理指南(基层版2024年)[J].中国全科医学，2024，27(20)2429-2436.D01:10.12114/i.issn.1007-9572.2024.0005.

2.中华人民共和国国家卫生健康委员会医政司.肥胖症诊疗指南(2024年版)[J].中华消化外科杂志, 2024, 23(10):1237-1260.DOI:10.3760/cma.j.cn115610-20241017-00455.

3.Chen Z, Iona A, Parish S, et al. Adiposity and risk of ischaemic and haemorrhagic stroke in 0.5 million Chinese men and women: a prospective cohort study. Lancet Glob Health 2018; 6: e630–e40. 9 Zhang X, Shu X

4.中国血脂管理指南修订联合专家委员会,李建军,赵水平,等.中国血脂管理指南(2023年)[J].中国循环杂志, 2023, 38(3):237-271.DOI:10.3969/j.issn.1000-3614.2023.03.001.

5.中华预防医学会慢性病预防与控制分会，中国营养学会营养与慢病控制分会，中华医学会心血管病学分会,等.正确认识胆固醇科学声明.中华预防医学杂志，2016，50(11):936-937

6.胡梦婕,的机卓玛,郑迪心,等.高血压、糖尿病、血脂异常人群运动处方临床路径[J/OL].中国循证医学杂志,1-8[2025-12-19].https://link.cnki.net/urlid/51.1656.R.20251126.2141.002.

7.Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Wharton S; STEP 5 Study Group. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10. PMID: 36216945; PMCID: PMC9556320.

8.Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. PMID: 35131037.

9.Gu W, Lu Y, Ye X, Yuan G, Liu D, Shen Z, Zu N, Mu Y. Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial. Diabetes Obes Metab. 2025 May;27(5):2540-2551. doi: 10.1111/dom.16253. Epub 2025 Mar 11. PMID: 40069849; PMCID: PMC11964988.

*腾讯医典内容团队出品